Table 1.
Patient and treatment characteristics (N = 159 patients)
| Baseline characteristics | ||
|---|---|---|
| Age, years | 59.0 | 30–81 |
| Age group, years | ||
| < 50 | 38 | 23.9% |
| 50 to < 60 | 44 | 27.5% |
| 60 to < 70 | 46 | 28.8% |
| ≥ 70 | 31 | 19.4% |
| Race | ||
| Non-Hispanic white | 80 | 50.3% |
| Hispanic | 40 | 25.2% |
| African-American | 17 | 10.7% |
| Asian | 15 | 9.4% |
| Others | 6 | 3.8% |
| Missing data | 1 | 0.6% |
| Breast cancer stage | ||
| I | 34 | 21.4% |
| II | 88 | 55.3% |
| III | 37 | 23.3% |
| ER, PR, HER2 status | ||
| ER+ or PR+, HER2- | 106 | 66.7% |
| HER2+ | 25 | 15.7% |
| ER-PR-HER2- | 28 | 17.6% |
| Type of chemotherapy | ||
| Neoadjuvant | 17 | 10.7% |
| Adjuvant | 142 | 89.3% |
| Chemotherapy regimen | ||
| AC-T | 56 | 35.2% |
| TC | 59 | 37.1% |
| AC-TH | 11 | 6.9% |
| TCH | 11 | 6.9% |
| Sequential A-T-C | 10 | 6.3% |
| Other non-HER2-targeted therapy | 6 | 3.8% |
| Other HER-2-targeted therapy | 6 | 3.8% |
| Anthracycline-containing regimen | ||
| No | 75 | 47.2% |
| Yes | 84 | 52.8% |
| Comorbidities | ||
| Hypertension | 54 | 34.0% |
| Arthritis | 47 | 29.6% |
| Depression | 31 | 19.5% |
| Circulation problem | 22 | 13.8% |
| Other cancers | 18 | 11.3% |
| Stomach disorders | 17 | 10.7% |
| Othera | ||
| Number of comorbidities ≥ 1 | 105 | 66.0% |
| Number of comorbidities ≥ 2 | 64 | 40.3% |
| Number of comorbidities ≥ 3 | 35 | 22.0% |
Values are presented as median and range, or number and percentage
ER estrogen receptor, PR progesterone receptor, HER2 human epidermal growth factor receptor 2, TC docetaxel plus cyclophosphamide, AC-T doxorubicin plus cyclophosphamide followed by paclitaxel, TCH docetaxel, carboplatin and trastuzumab, AC-TH doxorubicin plus cyclophosphamide followed by paclitaxel plus trastuzumab, A-T-C sequential doxorubicin, paclitaxel and cyclophosphamide
aOther: heart disease (N = 15, 9.4%); diabetes mellitus (N =12, 7.5%); glaucoma (N = 9, 5.7%); emphysema (N = 5, 3.1%); liver/kidney disease (N = 2, 1.3%); stroke (N = 1, 0.6%)